The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial

Leslie, W. S. et al. (2016) The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial. BMC Family Practice, 17(1), (doi: 10.1186/s12875-016-0406-2) (PMID:26879684) (PMCID:PMC4754868)

119081.pdf - Published Version
Available under License Creative Commons Attribution.



Background: Despite improving evidence-based practice following clinical guidelines to optimise drug therapy, Type 2 diabetes (T2DM) still exerts a devastating toll from vascular complications and premature death. Biochemical remission of T2DM has been demonstrated with weight loss around 15kg following bariatric surgery and in several small studies of non-surgical energy-restriction treatments. The non-surgical Counterweight-Plus programme, running in Primary Care where obesity and T2DM are routinely managed, produces >15 kg weight loss in 33 % of all enrolled patients. The Diabetes UK-funded Counterpoint study suggested that this should be sufficient to reverse T2DM by removing ectopic fat in liver and pancreas, restoring first-phase insulin secretion. The Diabetes Remission Clinical Trial (DiRECT) was designed to determine whether a structured, intensive, weight management programme, delivered in a routine Primary Care setting, is a viable treatment for achieving durable normoglycaemia. Other aims are to understand the mechanistic basis of remission and to identify psychological predictors of response. Methods/Design: Cluster-randomised design with GP practice as the unit of randomisation: 280 participants from around 30 practices in Scotland and England will be allocated either to continue usual guideline-based care or to add the Counterweight-Plus weight management programme, which includes primary care nurse or dietitian delivery of 12-20weeks low calorie diet replacement, food reintroduction, and long-term weight loss maintenance. Main inclusion criteria: men and women aged 20-65years, all ethnicities, T2DM 0-6years duration, BMI 27-45 kg/m2. Tyneside participants will undergo Magnetic Resonance (MR) studies of pancreatic and hepatic fat, and metabolic studies to determine mechanisms underlying T2DM remission. Co-primary endpoints: weight reduction ≥ 15 kg and HbA1c <48 mmol/mol at one year. Further follow-up at 2 years. Discussion: This study will establish whether a structured weight management programme, delivered in Primary Care by practice nurses or dietitians, is a viable treatment to achieve T2DM remission. Results, available from 2018 onwards, will inform future service strategy.

Item Type:Articles
Additional Information:The DiRECT study is funded as a Strategic Research Initiative by Diabetes UK.
Glasgow Author(s) Enlighten ID:Brosnahan, Miss Naomi and Lean, Professor Michael and Kean, Ms Sharon and McIlvenna, Ms Yvonne and Thom, Dr George and Sattar, Professor Naveed and Leslie, Dr Wilma and Ford, Professor Ian
Authors: Leslie, W. S., Ford, I., Sattar, N., Hollingsworth, K. G., Adamson, A., Sniehotta, F. F., McCombie, L., Brosnahan, N., Ross, H., Mathers, J. C., Peters, C., Thom, G., Barnes, A., Kean, S., McIlvenna, Y., Rodrigues, A., Rehackova, L., Zhyzhneuskaya, S., Taylor, R., and Lean, M. E.J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > General Practice and Primary Care
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:BMC Family Practice
Publisher:BioMed Central
ISSN (Online):1471-2296
Published Online:16 February 2016
Copyright Holders:Copyright © 2016 Leslie et al.
First Published:First published in BMC Family Practice 17:20
Publisher Policy:Reproduced under a creative commons license

University Staff: Request a correction | Enlighten Editors: Update this record